

PSC NO: 10 – Electricity
Consolidated Edison Company of New York, Inc.
Initial Effective Date: 11/01/2011

Leaf: 202
Revision: 0
Superseding Revision:

GENERAL RULES

24. Service Classification Riders (Available on Request) - Continued

RIDER J - BUSINESS INCENTIVE RATE - Continued

(A) Applicability – Continued

(3) Definitions - Continued

- (e) "Vacant Premises" is defined as a previously occupied building where at least 75 percent of the rentable commercial square foot area has been unoccupied for twelve consecutive months out of the 24 months preceding the first application for service in such building under this Rider and the building is receiving a substantial real property tax incentive, energy rebates under the Energy Cost Savings Program, or a comprehensive package of economic incentives.
- (f) "Attraction and Retention Customers" is defined as Customers who are receiving a comprehensive package of economic incentives in exchange for a long-term commitment to locate, remain or relocate in the Company's service area.
- (g) "Biomedical Research" is defined as research and development on use of cellular and molecular processes with a goal of creating products and solving health-related problems. Biomedical research includes research and development within the following disciplines: bioscience (adapting traditional research to commercial goals, studying the molecular, cellular and genetic causes of disease); biomedical and biological engineering (integrating physical, chemical, mathematical, computational science, and engineering principles to study biology, medicine, behavior and health); genomics (treatments based upon genetic manipulation); research instrumentation (screening, analysis, and computing used to assist in the research of disease and development of medicines and other treatments); translational medicine (application of research findings to commercially viable product development and to treatments that are directly applicable to human diseases); drug development (including research, development, and manufacturing of medicines and drug delivery); clinical research (studies of patient populations, analysis of treatments, and clinical trials); biomedical device development (development and manufacturing of medical instrumentation, supplies, imaging tools, and therapeutic devices); and biopharmacology (direct application of research to development of drug treatments).

Issued by: Robert N. Hoglund, Senior Vice President & Chief Financial Officer, New York, NY